Nehad El Salamouni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nehad El Salamouni has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Haibo Yu
University of Wollongong
9 shared publications - Lisanne M. Spenkelink
Molecular Horizons and School of Science, University of Wollongong, Wollongong, NSW, Australia.
4 shared publications - Jordan Cater
University of Wollongong
3 shared publications - Danielle Skropeta
University of Wollongong
2 shared publications Jordan H. Cater
School of Science
2 shared publications- Michael J. Kelso
University of Wollongong
2 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
VHH-Bench: A Benchmarking Framework for Evaluating Nanobody–Antigen Complex Predictions Across CDR3 Conformations
Accurate prediction of nanobody–antigen complex structures is critical for the development of diagnostic, therapeutic and biosensing applications. However, progress in this area have been constrained by the limited availability of experimentally determined nanobody–antigen complex structures. Recent advances in deep learning have enabled highly accurate prediction of protein structures and protein-protein complexes, yet accurate modelling of nanobody–antigen interactions remains challenging due to the diverse binding modes exhibited by nanobodies. Here, we present VHH‑Bench, a benchmarking workflow for the systematic evaluation of nanobody–antigen complex structure prediction methods. We curated a non-redundant dataset of experimentally resolved nanobody–antigen complexes and evaluated six state-of-the-art models: AlphaFold3, Boltz-2, Chai-1, ESMFold2, HelixFold3 and Protenix-v2. Complexes were stratified according to CDR3 conformation, enabling separate assessment of kinked and extended nanobody classes. Prediction performance varied substantially between models and conformational classes. Protenix-v2 achieved the highest overall docking accuracy, success rate and proportion of high-quality predictions, with its advantage most pronounced for nanobodies with extended CDR3 conformations. In contrast, all evaluated models showed reduced accuracy and higher failure rates for complexes containing kinked nanobodies. While increased stochastic sampling provided slight improvements in some cases, its overall impact was limited and did not substantially affect the relative performance ranking of the evaluated models. VHH-Bench provides an extensible and reproducible benchmarking workflow for standardised dataset curation, nanobody classification, model evaluation and confidence analysis, facilitating the rigorous assessment and future development of nanobody–antigen complex prediction methods. The VHH-Bench framework is available at https://github.com/haiboyugroup/VHH-Bench.
- 22 October 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessVHH-Bench: A Benchmarking Framework for Evaluating Nanobody–Antigen Complex Predictions Across CDR3 Conformations
Accurate prediction of nanobody–antigen complex structures is critical for the development of diagnostic, therapeutic and biosensing applications. However, progress in this area have been constrained by the limited availability of experimentally determined nanobody–antigen complex structures. Recent advances in deep learning have enabled highly accurate prediction of protein structures and protein-protein complexes, yet accurate modelling of nanobody–antigen interactions remains challenging due to the diverse binding modes exhibited by nanobodies. Here, we present VHH‑Bench, a benchmarking workflow for the systematic evaluation of nanobody–antigen complex structure prediction methods. We curated a non-redundant dataset of experimentally resolved nanobody–antigen complexes and evaluated six state-of-the-art models: AlphaFold3, Boltz-2, Chai-1, ESMFold2, HelixFold3 and Protenix-v2. Complexes were stratified according to CDR3 conformation, enabling separate assessment of kinked and extended nanobody classes. Prediction performance varied substantially between models and conformational classes. Protenix-v2 achieved the highest overall docking accuracy, success rate and proportion of high-quality predictions, with its advantage most pronounced for nanobodies with extended CDR3 conformations. In contrast, all evaluated models showed reduced accuracy and higher failure rates for complexes containing kinked nanobodies. While increased stochastic sampling provided slight improvements in some cases, its overall impact was limited and did not substantially affect the relative performance ranking of the evaluated models. VHH-Bench provides an extensible and reproducible benchmarking workflow for standardised dataset curation, nanobody classification, model evaluation and confidence analysis, facilitating the rigorous assessment and future development of nanobody–antigen complex prediction methods. The VHH-Bench framework is available at https://github.com/haiboyugroup/VHH-Bench.
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (5) , 2879-2888
Mechanistic Insights into Nanobody-Based Quenchbody Sensing via Structural Modeling and Molecular Simulations
Nanobody-based quenchbodies are powerful fluorescent sensors for detecting biomolecular targets. They rely on tryptophan residues in the antigen-binding site that can quench (darken) a fluorophore attached via a flexible linker; antigen binding displaces the fluorophore and increases the fluorescence. Quenchbodies targeting interleukin-6 (IL-6) exhibit variable fluorescence responses despite comparable antigen binding, prompting an investigation into the underlying mechanism. We combined data-driven structural prediction with molecular dynamics simulations and first benchmarked HelixFold3 against AlphaFold3 using nanobody-lysozyme complexes, finding that HelixFold3 provided more accurate models. We then used HelixFold3 to predict the nanobody-IL-6 structures. Our analyses revealed that low and nonresponders retain solvent-exposed tryptophan residues upon antigen binding, enabling continued fluorophore quenching and reduced fluorescence. In contrast, good responders bury these tryptophan residues, limiting quenching and enhancing the signal. These results show that integrating data-driven structural prediction with molecular dynamics simulations can decode quenchbody mechanisms and guide the rational design of improved biosensors.
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (5) , 2879-2888
Mechanistic Insights into Nanobody-Based Quenchbody Sensing via Structural Modeling and Molecular Simulations
Nanobody-based quenchbodies are powerful fluorescent sensors for detecting biomolecular targets. They rely on tryptophan residues in the antigen-binding site that can quench (darken) a fluorophore attached via a flexible linker; antigen binding displaces the fluorophore and increases the fluorescence. Quenchbodies targeting interleukin-6 (IL-6) exhibit variable fluorescence responses despite comparable antigen binding, prompting an investigation into the underlying mechanism. We combined data-driven structural prediction with molecular dynamics simulations and first benchmarked HelixFold3 against AlphaFold3 using nanobody-lysozyme complexes, finding that HelixFold3 provided more accurate models. We then used HelixFold3 to predict the nanobody-IL-6 structures. Our analyses revealed that low and nonresponders retain solvent-exposed tryptophan residues upon antigen binding, enabling continued fluorophore quenching and reduced fluorescence. In contrast, good responders bury these tryptophan residues, limiting quenching and enhancing the signal. These results show that integrating data-driven structural prediction with molecular dynamics simulations can decode quenchbody mechanisms and guide the rational design of improved biosensors.
- Open Access
- 18 February 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Mechanistic Insights into Nanobody-Based Quenchbody Sensing via Structural Modeling and Molecular Simulations
Nanobody-based quenchbodies are emerging as powerful tools for the sensitive and specific detection of biomolecular targets. These fluorescent sensors contain tryptophan residues in the antigen-binding site that can quench (darken) a fluorophore attached via a flexible linker. Upon antigen binding the fluorophore is displaced, resulting in an increase in intensity. Recent quenchbodies developed against the inflammatory cytokine interleukin-6 (IL-6) exhibit variable fluorescence responses despite comparable antigen binding. To investigate the molecular basis of this discrepancy, we combined data-driven structural prediction with physics-based molecular dynamics simulations. Using a benchmark dataset of nanobody–lysozyme complexes, we first established that HelixFold3 provides more accurate structural predictions than AlphaFold3. Leveraging this finding, we used HelixFold3 to model the structures of the IL6-binding quenchbodies. Our analyses revealed that low and non-responders exhibit solvent-exposed tryptophan residues upon antigen binding, notably tryptophan 110, allowing fluorophore quenching and reduced fluorescence. In contrast, good responders adopt conformations in which these tryptophan residues are largely buried, resulting in a more pronounced fluorescence increase upon antigen binding. Together, these results illustrate that integrating structural predictions with molecular dynamics simulations offer a powerful framework for decoding quenchbody mechanisms and advancing the rational development of highly responsive fluorescent sensors.
- 18 February 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMechanistic Insights into Nanobody-Based Quenchbody Sensing via Structural Modeling and Molecular Simulations
Nanobody-based quenchbodies are emerging as powerful tools for the sensitive and specific detection of biomolecular targets. These fluorescent sensors contain tryptophan residues in the antigen-binding site that can quench (darken) a fluorophore attached via a flexible linker. Upon antigen binding the fluorophore is displaced, resulting in an increase in intensity. Recent quenchbodies developed against the inflammatory cytokine interleukin-6 (IL-6) exhibit variable fluorescence responses despite comparable antigen binding. To investigate the molecular basis of this discrepancy, we combined data-driven structural prediction with physics-based molecular dynamics simulations. Using a benchmark dataset of nanobody–lysozyme complexes, we first established that HelixFold3 provides more accurate structural predictions than AlphaFold3. Leveraging this finding, we used HelixFold3 to model the structures of the IL6-binding quenchbodies. Our analyses revealed that low and non-responders exhibit solvent-exposed tryptophan residues upon antigen binding, notably tryptophan 110, allowing fluorophore quenching and reduced fluorescence. In contrast, good responders adopt conformations in which these tryptophan residues are largely buried, resulting in a more pronounced fluorescence increase upon antigen binding. Together, these results illustrate that integrating structural predictions with molecular dynamics simulations offer a powerful framework for decoding quenchbody mechanisms and advancing the rational development of highly responsive fluorescent sensors.
- Open Access
- 27 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Mechanistic Insights into Nanobody-Based Quenchbody Sensing via Structural Modeling and Molecular Simulations
Nanobody-based quenchbodies are emerging as powerful tools for the sensitive and specific detection of biomolecular targets. These fluorescent sensors contain tryptophan residues in the antigen-binding site that can quench (darken) a fluorophore attached via a flexible linker. Upon antigen binding the fluorophore is displaced, resulting in an increase in intensity. Recent quenchbodies developed against the inflammatory cytokine interleukin-6 (IL-6) exhibit variable fluorescence responses despite comparable antigen binding. To investigate the molecular basis of this discrepancy, we combined data-driven structural prediction with physics-based molecular dynamics simulations. Using a benchmark dataset of nanobody–lysozyme complexes, we first established that HelixFold3 provides more accurate structural predictions than AlphaFold3. Leveraging this finding, we used HelixFold3 to model the structures of the IL6-binding quenchbodies. Our analyses revealed that poor responders exhibit solvent-exposed tryptophan residues upon antigen binding, notably tryptophan 110, allowing fluorophore quenching and reduced fluorescence. In contrast, good responders adopt conformations in which these tryptophan residues are largely buried, resulting in a more pronounced fluorescence increase upon antigen binding. Together, these results illustrate that integrating structural predictions with molecular dynamics simulations offer a powerful framework for decoding quenchbody mechanisms and advancing the rational development of highly responsive fluorescent sensors.
- 27 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMechanistic Insights into Nanobody-Based Quenchbody Sensing via Structural Modeling and Molecular Simulations
Nanobody-based quenchbodies are emerging as powerful tools for the sensitive and specific detection of biomolecular targets. These fluorescent sensors contain tryptophan residues in the antigen-binding site that can quench (darken) a fluorophore attached via a flexible linker. Upon antigen binding the fluorophore is displaced, resulting in an increase in intensity. Recent quenchbodies developed against the inflammatory cytokine interleukin-6 (IL-6) exhibit variable fluorescence responses despite comparable antigen binding. To investigate the molecular basis of this discrepancy, we combined data-driven structural prediction with physics-based molecular dynamics simulations. Using a benchmark dataset of nanobody–lysozyme complexes, we first established that HelixFold3 provides more accurate structural predictions than AlphaFold3. Leveraging this finding, we used HelixFold3 to model the structures of the IL6-binding quenchbodies. Our analyses revealed that poor responders exhibit solvent-exposed tryptophan residues upon antigen binding, notably tryptophan 110, allowing fluorophore quenching and reduced fluorescence. In contrast, good responders adopt conformations in which these tryptophan residues are largely buried, resulting in a more pronounced fluorescence increase upon antigen binding. Together, these results illustrate that integrating structural predictions with molecular dynamics simulations offer a powerful framework for decoding quenchbody mechanisms and advancing the rational development of highly responsive fluorescent sensors.
- Open Access
- 18 June 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-11
Optimised nanobody-based quenchbodies for enhanced protein detection
Quenchbodies, antibodies labelled with fluorophores that increase in intensity upon antigen binding, offer great promise for biosensor development. Nanobody-based quenchbodies are particularly attractive due to their small size, ease of expression, high stability, rapid evolvability, and amenability to protein engineering. However, existing designs for protein detection show limited dynamic range, with fluorescence increases of only 1.1–1.4 fold. Here we identify the tryptophan residues in the nanobody complementarity-determining regions (CDRs) that are critical to quenchbody performance. Using a combination of rational design and molecular dynamics simulations, we developed an optimised nanobody scaffold with tryptophans introduced at key positions. We used this scaffold in an in vitro directed-evolution screen against human inflammatory cytokine interleukin-6 (IL-6). This yielded quenchbodies with 1.5–2.4-fold fluorescence increases, enabling IL-6 detection down to 1–2 nM. Our scaffold provides a valuable platform for developing biosensors for diverse protein targets, with applications in research, diagnostics, and environmental monitoring.
- 18 June 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-11
Open AccessOptimised nanobody-based quenchbodies for enhanced protein detection
Quenchbodies, antibodies labelled with fluorophores that increase in intensity upon antigen binding, offer great promise for biosensor development. Nanobody-based quenchbodies are particularly attractive due to their small size, ease of expression, high stability, rapid evolvability, and amenability to protein engineering. However, existing designs for protein detection show limited dynamic range, with fluorescence increases of only 1.1–1.4 fold. Here we identify the tryptophan residues in the nanobody complementarity-determining regions (CDRs) that are critical to quenchbody performance. Using a combination of rational design and molecular dynamics simulations, we developed an optimised nanobody scaffold with tryptophans introduced at key positions. We used this scaffold in an in vitro directed-evolution screen against human inflammatory cytokine interleukin-6 (IL-6). This yielded quenchbodies with 1.5–2.4-fold fluorescence increases, enabling IL-6 detection down to 1–2 nM. Our scaffold provides a valuable platform for developing biosensors for diverse protein targets, with applications in research, diagnostics, and environmental monitoring.
- 19 March 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (8) , 1762-1769
Active Site Plasticity of the Bacterial Sliding Clamp
The rise of antibiotic resistance poses a severe global threat, specifically due to the emergence of multiresistant bacteria (ESKAPE pathogens), which are responsible for countless deaths globally. Consequently, the development of novel antibiotics is in dire need. Targeting proteins essential to DNA replication is a promising pathway, making the β-sliding clamp (β-SC) an attractive target. Currently, there are no antibiotics on the market that target the β-SC. However, numerous compounds are being investigated to create an antibiotic with high potency against a broad range of bacterial species. Interestingly, most proposed compounds do not bind to the entire active site, which may reduce their potential as high-potency inhibitors. This is due to the active site residue Met at position 362, adopting a "closed" conformation, preventing inhibitors access into Subsite II of the active site. This study explored the effect of key residues on the plasticity of the β-SC active site using molecular dynamics and metadynamics simulations under different physiological states. Our results show that the Met gate exhibits flexibility and both open and closed states are thermodynamically and kinetically accessible.
- 19 March 2025
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 64 (8) , 1762-1769
Active Site Plasticity of the Bacterial Sliding Clamp
The rise of antibiotic resistance poses a severe global threat, specifically due to the emergence of multiresistant bacteria (ESKAPE pathogens), which are responsible for countless deaths globally. Consequently, the development of novel antibiotics is in dire need. Targeting proteins essential to DNA replication is a promising pathway, making the β-sliding clamp (β-SC) an attractive target. Currently, there are no antibiotics on the market that target the β-SC. However, numerous compounds are being investigated to create an antibiotic with high potency against a broad range of bacterial species. Interestingly, most proposed compounds do not bind to the entire active site, which may reduce their potential as high-potency inhibitors. This is due to the active site residue Met at position 362, adopting a "closed" conformation, preventing inhibitors access into Subsite II of the active site. This study explored the effect of key residues on the plasticity of the β-SC active site using molecular dynamics and metadynamics simulations under different physiological states. Our results show that the Met gate exhibits flexibility and both open and closed states are thermodynamically and kinetically accessible.
- Open Access
- 15 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Active Site Plasticity of the Bacterial Sliding Clamp
The rise of antibiotic resistance poses a severe global threat, specifically due to the emergence of multi- resistant bacteria named ESKAPE pathogens which are responsible for countless deaths globally. Consequently, the development of novel antibiotics is in dire need. Targeting proteins essential to DNA replication is a promising pathway, making the β-sliding clamp (β-SC) an attractive target. Currently, there are no antibiotics on the market that target the β-SC. However, numerous compounds are being investigated to create an antibiotic with high potency against a broad range of bacterial species. Interestingly, most proposed compounds do not bind to the entire active site which may reduce their potential as high potency inhibitors. This is due to the active site residue Met at position 362, adopting a “closed” conformation, preventing inhibitors access into Subsite II of the active site. This study explored the effect of key residues on the plasticity of the β-SC active site using molecular dynamics and metadynamics simulations under different physiological states. Our results show that the Met gate exhibits flexibility and both open and closed states are thermodynamically and kinetically accessible.
- 15 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessActive Site Plasticity of the Bacterial Sliding Clamp
The rise of antibiotic resistance poses a severe global threat, specifically due to the emergence of multi- resistant bacteria named ESKAPE pathogens which are responsible for countless deaths globally. Consequently, the development of novel antibiotics is in dire need. Targeting proteins essential to DNA replication is a promising pathway, making the β-sliding clamp (β-SC) an attractive target. Currently, there are no antibiotics on the market that target the β-SC. However, numerous compounds are being investigated to create an antibiotic with high potency against a broad range of bacterial species. Interestingly, most proposed compounds do not bind to the entire active site which may reduce their potential as high potency inhibitors. This is due to the active site residue Met at position 362, adopting a “closed” conformation, preventing inhibitors access into Subsite II of the active site. This study explored the effect of key residues on the plasticity of the β-SC active site using molecular dynamics and metadynamics simulations under different physiological states. Our results show that the Met gate exhibits flexibility and both open and closed states are thermodynamically and kinetically accessible.
- Open Access
- 19 June 2024
- Published by Wiley in FEBS Open Bio
- Vol. 15 (2) , 236-253
Nanobody engineering: computational modelling and design for biomedical and therapeutic applications
Nanobodies, the smallest functional antibody fragment derived from camelid heavy‐chain‐only antibodies, have emerged as powerful tools for diverse biomedical applications. In this comprehensive review, we discuss the structural characteristics, functional properties, and computational approaches driving the design and optimisation of synthetic nanobodies. We explore their unique antigen‐binding domains, highlighting the critical role of complementarity‐determining regions in target recognition and specificity. This review further underscores the advantages of nanobodies over conventional antibodies from a biosynthesis perspective, including their small size, stability, and solubility, which make them ideal candidates for economical antigen capture in diagnostics, therapeutics, and biosensing. We discuss the recent advancements in computational methods for nanobody modelling, epitope prediction, and affinity maturation, shedding light on their intricate antigen‐binding mechanisms and conformational dynamics. Finally, we examine a direct example of how computational design strategies were implemented for improving a nanobody‐based immunosensor, known as a Quenchbody. Through combining experimental findings and computational insights, this review elucidates the transformative impact of nanobodies in biotechnology and biomedical research, offering a roadmap for future advancements and applications in healthcare and diagnostics.
- 19 June 2024
- Published by Wiley in FEBS Open Bio
- Vol. 15 (2) , 236-253
Open AccessNanobody engineering: computational modelling and design for biomedical and therapeutic applications
Nanobodies, the smallest functional antibody fragment derived from camelid heavy‐chain‐only antibodies, have emerged as powerful tools for diverse biomedical applications. In this comprehensive review, we discuss the structural characteristics, functional properties, and computational approaches driving the design and optimisation of synthetic nanobodies. We explore their unique antigen‐binding domains, highlighting the critical role of complementarity‐determining regions in target recognition and specificity. This review further underscores the advantages of nanobodies over conventional antibodies from a biosynthesis perspective, including their small size, stability, and solubility, which make them ideal candidates for economical antigen capture in diagnostics, therapeutics, and biosensing. We discuss the recent advancements in computational methods for nanobody modelling, epitope prediction, and affinity maturation, shedding light on their intricate antigen‐binding mechanisms and conformational dynamics. Finally, we examine a direct example of how computational design strategies were implemented for improving a nanobody‐based immunosensor, known as a Quenchbody. Through combining experimental findings and computational insights, this review elucidates the transformative impact of nanobodies in biotechnology and biomedical research, offering a roadmap for future advancements and applications in healthcare and diagnostics.
- Open Access
- 27 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Nanobody Engineering: Computational Modelling and Design for Biomedical and Therapeutic Applications
Nanobodies, the smallest functional antibody fragment derived from camelid heavy-chain-only antibodies, have emerged as powerful tools for diverse biomedical applications. In this comprehensive review, we discuss the structural characteristics, functional properties, and computational approaches driving the design and optimisation of synthetic nanobodies. We explore their unique antigen-binding domains, highlighting the critical role of complementarity-determining regions in target recognition and specificity. This review further underscores the advantages of nanobodies over conventional antibodies from a biosynthesis perspective, including their small size, stability, and solubility, which make them ideal candidates for economical antigen capture in diagnostics, therapeutics, and biosensing. We discuss the recent advancements in computational methods for nanobody modelling, epitope prediction, and affinity maturation, shedding light on their intricate antigen-binding mechanisms and conformational dynamics. Finally, we examine a direct example of how computational design strategies were implemented for improving a nanobody-based immunosensor, known as a Quenchbody. Through combining experimental findings and computational insights, this review elucidates the transformative impact of nanobodies in biotechnology and biomedical research, offering a roadmap for future advancements and applications in healthcare and diagnostics.
- 27 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessNanobody Engineering: Computational Modelling and Design for Biomedical and Therapeutic Applications
Nanobodies, the smallest functional antibody fragment derived from camelid heavy-chain-only antibodies, have emerged as powerful tools for diverse biomedical applications. In this comprehensive review, we discuss the structural characteristics, functional properties, and computational approaches driving the design and optimisation of synthetic nanobodies. We explore their unique antigen-binding domains, highlighting the critical role of complementarity-determining regions in target recognition and specificity. This review further underscores the advantages of nanobodies over conventional antibodies from a biosynthesis perspective, including their small size, stability, and solubility, which make them ideal candidates for economical antigen capture in diagnostics, therapeutics, and biosensing. We discuss the recent advancements in computational methods for nanobody modelling, epitope prediction, and affinity maturation, shedding light on their intricate antigen-binding mechanisms and conformational dynamics. Finally, we examine a direct example of how computational design strategies were implemented for improving a nanobody-based immunosensor, known as a Quenchbody. Through combining experimental findings and computational insights, this review elucidates the transformative impact of nanobodies in biotechnology and biomedical research, offering a roadmap for future advancements and applications in healthcare and diagnostics.
- 27 November 2017
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 149 (1) , 127-139
Synthesis and evaluation of new phenolic derivatives as antimicrobial and antioxidant agents
- 27 November 2017
- Published by Springer Nature in Monatshefte für Chemie - Chemical Monthly
- Vol. 149 (1) , 127-139
Synthesis and evaluation of new phenolic derivatives as antimicrobial and antioxidant agents